Zhejiang Jingxin Pharmaceutical Co Ltd - Asset Resilience Ratio
Zhejiang Jingxin Pharmaceutical Co Ltd (002020) has an Asset Resilience Ratio of 7.95% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Zhejiang Jingxin Pharmaceutical Co Ltd (002020) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2025)
This chart shows how Zhejiang Jingxin Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Zhejiang Jingxin Pharmaceutical Co Ltd assets under control.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Jingxin Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Zhejiang Jingxin Pharmaceutical Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥632.08 Million | 7.95% |
| Total Liquid Assets | CN¥632.08 Million | 7.95% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Jingxin Pharmaceutical Co Ltd maintains only 7.95% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Jingxin Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhejiang Jingxin Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Shenzhen Kangtai Biological Products Co Ltd
SHE:300601 |
Drug Manufacturers - Specialty & Generic | 12.99% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
|
ChengDa Pharmaceuticals Co. Ltd.
SHE:301201 |
Drug Manufacturers - Specialty & Generic | 32.14% |
Annual Asset Resilience Ratio for Zhejiang Jingxin Pharmaceutical Co Ltd (2001–2025)
The table below shows the annual Asset Resilience Ratio data for Zhejiang Jingxin Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.93% | CN¥318.96 Million ≈ $46.67 Million |
CN¥8.12 Billion ≈ $1.19 Billion |
-5.83pp |
| 2024-12-31 | 9.76% | CN¥827.66 Million ≈ $121.11 Million |
CN¥8.48 Billion ≈ $1.24 Billion |
+7.87pp |
| 2023-12-31 | 1.89% | CN¥150.96 Million ≈ $22.09 Million |
CN¥7.99 Billion ≈ $1.17 Billion |
-3.09pp |
| 2022-12-31 | 4.98% | CN¥366.89 Million ≈ $53.69 Million |
CN¥7.36 Billion ≈ $1.08 Billion |
-1.60pp |
| 2021-12-31 | 6.58% | CN¥422.40 Million ≈ $61.81 Million |
CN¥6.42 Billion ≈ $938.77 Million |
-14.22pp |
| 2020-12-31 | 20.80% | CN¥1.18 Billion ≈ $172.50 Million |
CN¥5.67 Billion ≈ $829.15 Million |
-13.83pp |
| 2019-12-31 | 34.64% | CN¥1.95 Billion ≈ $285.11 Million |
CN¥5.63 Billion ≈ $823.13 Million |
+5.69pp |
| 2018-12-31 | 28.95% | CN¥1.45 Billion ≈ $211.45 Million |
CN¥4.99 Billion ≈ $730.45 Million |
-4.60pp |
| 2017-12-31 | 33.54% | CN¥1.65 Billion ≈ $240.72 Million |
CN¥4.90 Billion ≈ $717.61 Million |
+14.70pp |
| 2016-12-31 | 18.84% | CN¥620.00 Million ≈ $90.73 Million |
CN¥3.29 Billion ≈ $481.52 Million |
+6.03pp |
| 2015-12-31 | 12.81% | CN¥376.65 Million ≈ $55.12 Million |
CN¥2.94 Billion ≈ $430.20 Million |
-4.04pp |
| 2014-12-31 | 16.86% | CN¥348.00 Million ≈ $50.92 Million |
CN¥2.06 Billion ≈ $302.12 Million |
+16.85pp |
| 2012-12-31 | 0.00% | CN¥50.70K ≈ $7.42K |
CN¥1.30 Billion ≈ $190.37 Million |
0.00pp |
| 2011-12-31 | 0.01% | CN¥73.61K ≈ $10.77K |
CN¥1.19 Billion ≈ $174.51 Million |
-3.27pp |
| 2001-12-31 | 3.28% | CN¥5.00 Million ≈ $731.66K |
CN¥152.50 Million ≈ $22.32 Million |
-- |
About Zhejiang Jingxin Pharmaceutical Co Ltd
Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemi… Read more